<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160952</url>
  </required_header>
  <id_info>
    <org_study_id>SPO-I-08-CN-041-C</org_study_id>
    <secondary_id>ITRFUN4046</secondary_id>
    <nct_id>NCT01160952</nct_id>
  </id_info>
  <brief_title>Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation</brief_title>
  <official_title>Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Renmin Hospital of Zhongshan Guangdong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou General Hospital of Guangzhou Military Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  The primary objective of this study is to evaluate the efficacy and safety profile of&#xD;
           itraconazole as in primary prophylaxis&#xD;
&#xD;
        -  The second objective of this study is to find the difference between long-term versus&#xD;
           short-term sequential therapy of Itraconazole (intravenous followed by oral&#xD;
           itraconazole) as primary prophylaxis of invasive fungal infections (IFI) in patients&#xD;
           undergoing allogeneic stem cell transplantation (allo-SCT)&#xD;
&#xD;
        -  also to explore the relationship between the incidence of IFI with plasma concentrations&#xD;
           of itraconazole and hydroxy-itraconazole&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Invasive fungal infections (IFI) remain the major cause of death among neutropenic patients&#xD;
      receiving high dose chemotherapy or allo-SCT. Especially, patients undergoing allo-SCT&#xD;
      generally receive intensive immunosuppressive therapy, which make those patients at high risk&#xD;
      of developing IFI.&#xD;
&#xD;
      Prompt intensive antifungal therapy may increase the incidence rate of IFI and improved&#xD;
      responses and survival. Antifungal prophylaxis has been recommended in patients undergoing&#xD;
      allo-SCT by Infectious diseases society of America (IDSA) and Chinese guidelines for the&#xD;
      diagnosis and management of IFI in patients with hematologic/malignant tumor (revised).&#xD;
&#xD;
      Few studies have addressed the role of previous IFI in the feasibility of stem cell&#xD;
      transplant, or the secondary prophylaxis with antifungal drugs in preventing recurrence of&#xD;
      infection after transplantation. However, given the lack of prospective studies, the role of&#xD;
      primary antifungal prevention and the course of treatment remain unclear.&#xD;
&#xD;
      Itraconazole is a wide-spectrum triazole antifungal agent active against Candida albicans,&#xD;
      non-albicans, Aspergillus spp., Blastomyces dermatitidis, Blastomyces coccidioides,&#xD;
      Cryptococcus neoformans, Sporothrix schenkii, Paracoccidioides brasiliensis, Histoplasma spp.&#xD;
      and various kinds of yeast fungi and mycetes.&#xD;
&#xD;
      The role of itraconazole in IFI prophylaxis has been proved by many interventional studies.&#xD;
      However the optimal course of prophylaxis is still unknown，especially in China. In this&#xD;
      prospective, multicentric study of primary antifungal prevention, long-term or short-term&#xD;
      sequential therapy (intravenous followed by oral itraconazole) will be given at standard dose&#xD;
      to patients undergoing allogeneic stem cell transplantation to assess the efficacy and safety&#xD;
      of itraconazole in primary prophylaxis, and to analysis the relationship between the&#xD;
      incidence rate of IFI with plasma concentrations of itraconazole and hydroxy-itraconazole.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy evaluation</measure>
    <time_frame>90 days</time_frame>
    <description>the success rate of prophylaxis therapy by itraconazole</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>group difference evaluation</measure>
    <time_frame>90 days</time_frame>
    <description>efficacy difference between long-term and short-term groups per success rate at day 90</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hematological Diseases</condition>
  <condition>Allogeneic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>long-term group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>long-term group refers to prophylaxis by using itraconazole for up to 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>short term group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>short term group refers to prophylaxis by itraconazole for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itraconazole</intervention_name>
    <description>the two groups are defined by different treatment duration</description>
    <arm_group_label>long-term group</arm_group_label>
    <arm_group_label>short term group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman between 14 and 60 years of age, inclusive&#xD;
&#xD;
          -  Patients who affected by hematological diseases, receiving allo-SCT&#xD;
&#xD;
          -  Patients with no previous proven or probable invasive fungal infections. Patients&#xD;
             without microbiological evidence but with effective anti-fungal therapy history are&#xD;
             inclusive&#xD;
&#xD;
          -  Subjects (or their legally acceptable representatives) must have signed an informed&#xD;
             consent document indicating that they understand the purpose of and procedures&#xD;
             required for the study and are willing to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently taking the contra-indicated medications such as teldane, astemizol,&#xD;
             cisapride and HMG-CoA reductase inhibitor（e.g. Simvastatin, lovastatin, oral Midazolam&#xD;
             and Triazolam）&#xD;
&#xD;
          -  History of allergy or intolerance to imidazole or azoles anti-fungal agents (e.g.&#xD;
             Fluconazol, Itraconazole, Ketoconazole, Miconazole, Clotrimazole)&#xD;
&#xD;
          -  Pregnant women, lactating women or women of child bearing potential without applying&#xD;
             valid contraceptive measures&#xD;
&#xD;
          -  Patients with current cardiac dysfunction (especially with congestive heart failure)&#xD;
             or with the history of congestive heart failure&#xD;
&#xD;
          -  Patients with severe liver dysfunction (aminotransferase levels &gt;= 5 times the upper&#xD;
             limit of normal and total bilirubin level &gt;= 3mg/dL(51.3 μmol/L); or the severity of&#xD;
             liver dysfunction does not match this criteria but the patient is in bad condition and&#xD;
             not suitable for this trial( doctors make the decision);&#xD;
&#xD;
          -  Patients with renal insufficiency having serum Ccr level &lt;30ml/min, calculated from&#xD;
             the following formula:&#xD;
&#xD;
        Male: Ccr (ml/min)=(140-age)×weight (kg) /(0.8136×Crea (μmol/L) ) Female:Ccr&#xD;
        (ml/min)=(140-age)×weight (kg) ×0.85/(0.8136× Crea (μmol/L) )&#xD;
&#xD;
          -  Patients received any experimental drug within 14 days before the planned start of&#xD;
             treatment.&#xD;
&#xD;
          -  Patients with bad whole body status and not suitable for the trial (doctors make the&#xD;
             decision)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Xiao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou General Hospital of Guangzhou Military Command</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yonghua Li, MD</last_name>
    <phone>8613751880527</phone>
    <email>lyhood@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaohui Zeng, Pharm D</last_name>
    <phone>8613560327666</phone>
    <email>gzlcyljd@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangzhou General Hospital of Guangzhou Military Command</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yonghua Li, MD</last_name>
      <phone>8613751880527</phone>
      <email>lyhood@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaohui Zeng, Pharm D</last_name>
      <phone>8613560327666</phone>
      <email>gzlcyljd@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yang Xiao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004 Feb 15;103(4):1527-33. Epub 2003 Oct 2.</citation>
    <PMID>14525770</PMID>
  </reference>
  <reference>
    <citation>Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo MC. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003 May 6;138(9):705-13.</citation>
    <PMID>12729424</PMID>
  </reference>
  <reference>
    <citation>Chinese guideline for the diagnosis and management of IFI in patients with hematologic/maliglant tumor (revised). Chinese journal of internal medicine 2007，46(7):607-610.</citation>
  </reference>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>July 12, 2010</study_first_submitted>
  <study_first_submitted_qc>July 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2010</study_first_posted>
  <last_update_submitted>July 23, 2010</last_update_submitted>
  <last_update_submitted_qc>July 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jian Liu (President of the hospital)</name_title>
    <organization>Guangzhou General Hospital of Guangzhou Military Command</organization>
  </responsible_party>
  <keyword>primary prophylaxis</keyword>
  <keyword>itraconazole</keyword>
  <keyword>stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

